Wells Fargo & Company Aridis Pharmaceuticals, Inc. Put Options Transaction History
Wells Fargo & Company
- $434 Billion
- Q3 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding ARDS
# of Institutions
2Shares Held
50.2KCall Options Held
0Put Options Held
0About Aridis Pharmaceuticals, Inc.
- Ticker ARDS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 17,701,600
- Description
- Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the...